SEOM Clinical Guidelines for the Treatment of Non-small Cell Lung Cancer (2018)

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2018 Nov 18

PMID 30446985

Citations 69

Authors

M Majem

O Juan

A Insa

N Reguart

J M Trigo

E Carcereny

R Garcia-Campelo

Y Garcia

M Guirado

M Provencio

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value.

Citing Articles

Peripheral Extracellular Vesicles for Diagnosis and Prognosis of Resectable Lung Cancer: The LUCEx Study Protocol.

Rodriguez-Sanz J, Munoz-Gonzalez N, Cubero J, Ordonez P, Gil V, Langarita R J Clin Med. 2025; 14(2).

PMID: 39860417 PMC: 11765880. DOI: 10.3390/jcm14020411.

A lung cancer diagnosis and treatment dataset with geno- and phenotypical characteristics of the patient.

Rios-Sanchez B, Vigueras G, Garcia A, Gomez-Bravo D, Menasalvas E, Torrente M Data Brief. 2024; 57:111167.

PMID: 39736907 PMC: 11683279. DOI: 10.1016/j.dib.2024.111167.

Explainable Machine Learning Predictions for the Benefit From Chemotherapy in Advanced Non-Small Cell Lung Cancer Without Available Targeted Mutations.

Shuang Z, Xingyu X, Yue C, Mingjing Y Clin Respir J. 2024; 18(12):e70044.

PMID: 39696772 PMC: 11655385. DOI: 10.1111/crj.70044.

Differentiation of pathological subtypes and Ki-67 and TTF-1 expression by dual-energy CT (DECT) volumetric quantitative analysis in non-small cell lung cancer.

Wu Y, Li J, Ding L, Huang J, Chen M, Li X Cancer Imaging. 2024; 24(1):146.

PMID: 39456114 PMC: 11515807. DOI: 10.1186/s40644-024-00793-6.

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach.

Di Pressa F, Perrone F, Benini A, Lohr F, Tiseo M, Bruni A Explor Target Antitumor Ther. 2024; 5(3):449-464.

PMID: 38966183 PMC: 11220311. DOI: 10.37349/etat.2024.00228.

References

Videtic G, Donington J, Giuliani M, Heinzerling J, Karas T, Kelsey C . Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017; 7(5):295-301. DOI: 10.1016/j.prro.2017.04.014. View

Lilenbaum R, Herndon 2nd J, List M, Desch C, Watson D, Miller A . Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2004; 23(1):190-6. DOI: 10.1200/JCO.2005.07.172. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G . Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One. 2012; 7(5):e37229. PMC: 3355109. DOI: 10.1371/journal.pone.0037229. View

Mok T, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22):2244-2250. DOI: 10.1200/JCO.2018.78.7994. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

Kalemkerian G, Narula N, Kennedy E, Biermann W, Donington J, Leighl N . Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association.... J Clin Oncol. 2018; 36(9):911-919. DOI: 10.1200/JCO.2017.76.7293. View

Wozniak A, Crowley J, Balcerzak S, Weiss G, Spiridonidis C, Baker L . Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(7):2459-65. DOI: 10.1200/JCO.1998.16.7.2459. View

10.

Weickhardt A, Scheier B, Burke J, Gan G, Lu X, Bunn Jr P . Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012; 7(12):1807-1814. PMC: 3506112. DOI: 10.1097/JTO.0b013e3182745948. View

11.

Rusch V, Giroux D, Kraut M, Crowley J, Hazuka M, Winton T . Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007; 25(3):313-8. DOI: 10.1200/JCO.2006.08.2826. View

12.

Blackmon S, Cooke D, Whyte R, Miller D, Cerfolio R, Farjah F . The Society of Thoracic Surgeons Expert Consensus Statement: A Tool Kit to Assist Thoracic Surgeons Seeking Privileging to Use New Technology and Perform Advanced Procedures in General Thoracic Surgery. Ann Thorac Surg. 2016; 101(3):1230-7. DOI: 10.1016/j.athoracsur.2016.01.061. View

13.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

14.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

15.

Park J, Kim S, Ahn J, Suh C, Lee J, Jang J . Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33):5233-9. DOI: 10.1200/JCO.2007.10.8134. View

16.

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

17.

Mok T, Kim S, Wu Y, Nakagawa K, Yang J, Ahn M . Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017; 35(36):4027-4034. DOI: 10.1200/JCO.2017.73.9250. View

18.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

19.

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View

20.

Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N . Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol. 2004; 15(3):419-26. DOI: 10.1093/annonc/mdh087. View